Neil Goldenberg, MD, PhD is Chief Research Officer of All Children’s Research Institute and Associate Dean for Research at Johns Hopkins All Children’s Hospital (St. Petersburg, FL, USA), where he directs clinical and academic programs in both thrombosis and stroke and oversees a clinical coordinating center, data coordinating center, and biorepository focused on pediatric multicenter studies. He is a Professor of Pediatrics and Medicine at Johns Hopkins University.
Dr. Goldenberg is trained as both a pediatrician and an internist, and completed fellowship training in pediatric hematology, oncology and bone marrow transplantation at the University Colorado, where he earned a PhD in clinical investigation and pursued laboratory-based research on novel assays of coagulation and fibrinolysis as part of his PhD thesis. Prior to joining Hopkins in 2012, Dr. Goldenberg served as a Medical Safety Officer and Director of Clinical Science and Safety at CPC Clinical Research, an academic research organization providing design expertise and full-service management for pharmaceutic industry- and academically-sponsored multicenter trials.
Over the past 15 years, Dr. Goldenberg has served on numerous recent national/international guideline panels and committees in pediatric and adult venous thromboembolism (VTE) and ischemic stroke, via the American Heart Association, American College of Chest Physicians, and International Society on Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SSC). He is the present chair of the ISTH Pediatric/Neonatal SSC, and also chairs/recently chaired the Data and Safety Monitoring Committee for the pediatric apixaban program (BMS/Pfizer) as well as Steering Committees for the following multicenter trials: dalteparin in the treatment of pediatric cancer-associated VTE (Eisai/Pfizer); edoxaban in the prevention of thromboembolic events in children with cardiac disease (Daiici Sankyo); cangrelor for perioperative prevention of systemic to pulmonary artery shunt occlusion in infants undergoing congenital heart surgery (Chiesi); enoxaparin thromboprophylaxis in children hospitalized for COVID-19 (Johns Hopkins All Children’s Foundation); and cilostozol/L-carnitine for claudication in adult peripheral vascular disease (Otsuka). Dr. Goldenberg is also the overall Principal Investigator of the NIH-sponsored Kids-DOTT trial (duration of anticoagulation for provoked VTE in patients <21 years old).
Dr. Goldenberg’s main interests include: innovative clinical trial design and analytic methods; feasibility analysis; recruitment and retention challenges and solutions; real-time remoting monitoring; data and endpoint quality assurance; bivariate endpoint analysis of net clinical benefit in antithrombotic trials; surrogate endpoints/biologic correlates using coagulation and fibrinolysis assays; and prognostic biomarker discovery and validation in pediatric and young adult VTE.